Drug intelligence / Profile preview

Anbaixing

Development stage: Unknown
Lead developer: BioRay
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

Anbaixing (安佰欣) is a biosimilar monoclonal antibody developed by Hisun BioRay that targets the interleukin-6 receptor (IL-6R). As a biosimilar of tocilizumab, it acts as an IL-6R antagonist, blocking the signaling of the pro-inflammatory cytokine interleukin-6. It is primarily indicated for the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis. The drug has received marketing approval in China, where Hisun BioRay operates end-to-end R&D and manufacturing capabilities for its portfolio of autoimmune and oncology treatments.

Brand names: AnbaixingAnbaixin
Other names: 安佰欣tocilizumab biosimilar

Targets

IL-6R (Interleukin-6 receptor subunit alpha)

Beyond the preview

Go deeper on Anbaixing.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anbaixing.

Explore the full profile